News | November 28, 2025
Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GV20 received an upfront payment and is eligible for additional milestone payments
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
The fresh capital will propel Cordance into its first-in-human clinical trial
Subscribe To Our Newsletter & Stay Updated
